stockrow
Friday 6 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.72
1.70
+8.49%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) P/E ratio
Replimune Group, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)